Fayyaz Hussain Qureshi, Sajjad Hussain Qureshi, Tayyaba Zia, Fajr Khawaja


Huntington's disease (HD) is an incurable lethal inherited neurological disorder of brain cells caused by increased CAG repeats in the huntingtin gene. It is the disease of mind and body which causes uncontrolled movements, loss of intellectual faculties, and emotional disturbance leading to eventual death. HD is incurable, but treatment is available for the symptoms of this disease. Latest technologies and techniques are used to diagnose HD. Neuroimaging and genetic testing are two important diagnoses techniques are available to measure the progress of the disease at any later stage. Drastic research is underway to control the disease with neuro-transplantation and neuro-surgery as a potential treatment in future to cure HD. The advancements in science and technologies and research on HD have indicated bright chances of cure. In the future, this disease seems to become curable Huntington's disease.


Article visualizations:

Hit counter


Huntington’s disease, diagnosis, symptoms and treatment

Full Text:



Bates G., Harper P., Jones L. (2002). Huntington's Disease. Oxford University Press, New York.

Briggs A, Sculpher M. (1998). An introduction to Markov modelling for economic evaluation. Pharmacoeconomics; 13(4):397-409.

Brinkman R. R., Mezei M. M., Theilmann J., Almqvist E., Hayden M. R. (1997). The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet 60:1202–1210.

Djousse L., Knowlton B., Cupples L. A., Marder K., Shoulson I., Myers R. H. (2002). Weight loss in early stage of Huntington's disease. Neurology.; 59: 1325–30.

Kremer B (2002). "Clinical neurology of Huntington's disease". - Third Edition. Oxford: Oxford University Press. pp. 28–53.

Montoya A., Price B. H., Menear M., Lepage M. (2006). Brain imaging and cognitive dysfunctions in Huntington's disease. J Psychiatry Neurosci 31 (1): 21–9.

Passarge, E. (2001). Color Atlas of Genetics (2nd ed.). Thieme. p. 142

Paleacu D., Giladi N., Moore O., Stern A., Honigman S., Badarny S. (2004). Tetrabenazine treatment in movement disorders. Clin Neuropharmacol. Sep-Oct; 27(5):230-3.

Potter N. T., Spector E. B., Prior T. W. (2004). Technical standards and guidelines for Huntington disease testing. Genet Med.; 6: 61–5.

Pratley R. E., Salbe A. D., Ravussin E., Caviness J. N. (2000). Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol.; 47: 64–70.

Robbins A. O., Ho A. K., Barker R. A. (2006). Weight changes in Huntington's disease. Eur J Neurol.; 13: e7.

Rao A. K., Muratori L., Louis E. D., Moskowitz C. B., Marder K. S. (2009). Clinical measurement of mobility and balance impairments in Huntington's disease: validity and responsiveness. Gait Posture 29 (3): 433–6

Schneider S. A., Walker R. H., Bhatia K. P. (2007). The Huntington's disease-like syndromes: what to consider in patients with a negative Huntington's disease gene test. Nat Clin Pract Neurol 3 (9): 517–25.

Scott J. G., Mihalopoulos C., Erskine H. E., Roberts J., Rahman A. (2016). Childhood mental and developmental disorders. In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, eds. Mental, neurological, and substance use disorders: disease control priorities. Vol 4, 3rd ed. International Bank for Reconstruction and Development, World Bank:145-61. doi:10.1596/978-1-4648-0426- 7_ch8

Semaka A., Creighton S., Warby S., Hayden M. R. (2006). Predictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet. 70: 283–94.

Walker F. O. (2007). Huntington's disease. Lancet volume 369 issue (9557): 218-228

Chen W., Cheng X., Fu Y., Zhao M., McGinley J., Westenberger A. et al. (2020). Rethinking monogenic neurological diseases BMJ; 371: m3752 doi:10.1136/bmj.m3752


Home - Huntington’s Disease Drug Works. (2022). Retrieved 23 March 2022, from

Imagining The Brain: Art and Science competition for Sixth Form College students; Focus on neurodegeneration. (2022). Retrieved 23 March 2022, from

Huntington's disease - Wikimedia Commons. (2022). Retrieved 23 March 2022, from's_disease_(5880985560).jpg

Neurodegenerative Disease Market | 2022 - 27 | Industry Share, Size, Growth - Mordor Intelligence. (2022). Retrieved 23 March 2022, from

Huntington’s Disease - Gene Therapy - uniQure. (2022). Retrieved 23 March 2022, from

Leadership — Hereditary Disease Foundation. (2022). Retrieved 23 March 2022, from

Hereditary Disease Foundation. (2022). Retrieved 23 March 2022, from

Huntington's Disease Association. (2022). Retrieved 23 March 2022, from

Huntington’s Disease (2022). Retrieved 23 March 2022, from

Huntington's disease. (2022). Retrieved 23 March 2022, from

Autosomal Dominant (2022). Retrieved 23 March 2022, from



  • There are currently no refbacks.

Copyright (c) 2022 Fayyaz Hussain Qureshi, Sajjad Hussain Qureshi, Tayyaba Zia, Fajr Khawaja

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2019 - 2023. European Journal of Public Health Studies (ISSN 2668-1056/ISSN-L 2668-1056) is a registered trademark of Open Access Publishing Group. All rights reserved.

This journal is a serial publication uniquely identified by an International Standard Serial Number (ISSN) serial number certificate issued by Romanian National Library. All the research works are uniquely identified by a CrossRef DOI digital object identifier supplied by indexing and repository platforms. All the research works published on this journal are meeting the Open Access Publishing requirements and standards formulated by Budapest Open Access Initiative (2002), the Bethesda Statement on Open Access Publishing (2003) and Berlin Declaration on Open Access to Knowledge in the Sciences and Humanities (2003) and can be freely accessed, shared, modified, distributed and used in educational, commercial and non-commercial purposes under a Creative Commons Attribution 4.0 International License. Copyrights of the published research works are retained by authors.